Barinthus Historical Financial Ratios
| BRNS Stock | 1.04 0.03 2.97% |
Barinthus Biotherapeutics is presently reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.54 or Days Sales Outstanding of 2.2 K will help investors to properly organize and evaluate Barinthus Biotherapeutics financial condition quickly.
Barinthus |
About Barinthus Financial Ratios Analysis
Barinthus BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Barinthus Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Barinthus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Barinthus Biotherapeutics history.
Barinthus Biotherapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Barinthus Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Barinthus Biotherapeutics sales, a figure that is much harder to manipulate than other Barinthus Biotherapeutics plc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Barinthus Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Barinthus Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Barinthus Biotherapeutics plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Barinthus Biotherapeutics' Graham Net Net is comparatively stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Graham Number | 4.59 | 14.46 | 16.63 | 15.8 | Receivables Turnover | 3.66 | 0.1 | 0.12 | 0.11 |
Barinthus Biotherapeutics fundamentals Correlations
Click cells to compare fundamentals
Barinthus Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Barinthus Biotherapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Days Sales Outstanding | 244.25 | 9.7K | 99.66 | 3.6K | 3.3K | 2.2K | |
| Ev To Sales | 0.78 | 769.91 | (2.19) | 15.63 | 14.06 | 13.36 | |
| Roic | (0.47) | (0.17) | (0.0979) | (0.39) | (0.36) | (0.37) | |
| Research And Ddevelopement To Revenue | 2.3 | 61.08 | 0.92 | 51.64 | 46.47 | 48.8 | |
| Capex To Revenue | 0.0608 | 4.28 | 0.14 | 6.75 | 6.07 | 6.38 | |
| Interest Coverage | (5.57) | (16.95) | (212.68) | (3.0K) | (3.4K) | (3.3K) | |
| Capex To Operating Cash Flow | (0.0266) | (0.0352) | (0.43) | (0.11) | (0.12) | (0.13) | |
| Income Quality | 0.61 | 0.64 | (2.71) | 0.69 | 0.8 | 0.84 | |
| Roe | 0.47 | (0.2) | 0.022 | (0.39) | (0.45) | (0.43) | |
| Ev To Operating Cash Flow | (0.34) | (6.33) | 6.8 | (0.25) | (0.22) | (0.21) | |
| Return On Tangible Assets | (0.35) | (0.21) | 0.0233 | (0.41) | (0.37) | (0.39) | |
| Ev To Free Cash Flow | (0.33) | (6.12) | 4.77 | (0.22) | (0.2) | (0.21) | |
| Net Debt To E B I T D A | (0.22) | 4.32 | (28.98) | 1.82 | 2.09 | 2.19 | |
| Current Ratio | 6.27 | 20.32 | 17.4 | 12.45 | 11.21 | 9.48 | |
| Receivables Turnover | 1.49 | 0.0377 | 3.66 | 0.1 | 0.12 | 0.11 | |
| Debt To Equity | (1.24) | 0.0286 | 0.0361 | 0.0695 | 0.0625 | 0.0656 | |
| Debt To Assets | 0.92 | 0.0257 | 0.0325 | 0.0605 | 0.0696 | 0.0661 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.